FIELD: medicine.
SUBSTANCE: inventions group relates to medicine, namely to therapy, and can be used to inhibit phosphate uptake in the gastrointestinal tract. The method for the invention comprises enterally administering to a patient an effective amount of an NHE3 inhibitor. The use of the invention relates to the use of an NHE inhibitor in the manufacture of a medicament for inhibiting phosphate uptake in the gastrointestinal tract.
EFFECT: use of inventions makes it possible to reduce serum phosphorus and serum creatinine, to reduce urinary phosphorus excretion.
31 cl, 14 tbl, 16 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | 2014 |
|
RU2675364C2 |
| COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL DISEASES | 2013 |
|
RU2684097C2 |
| METHODS FOR DETERMINING EFFICACY OF LIGANDS OF SODIUM/PROTON ANTIPORTERS | 2009 |
|
RU2519345C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2733720C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2769701C2 |
| SELF-DELIVERED RNAI COMPOUNDS OF REDUCED SIZE | 2011 |
|
RU2615143C2 |
| TARGETED CONJUGATES AND PARTICLES AND COMPOSITIONS THEREOF | 2015 |
|
RU2695220C2 |
| METHOD OF TUMOUR TREATMENT IN SUBJECT | 2006 |
|
RU2404193C2 |
| CERTAIN PROTEIN KINASE INHIBITORS | 2017 |
|
RU2738837C2 |
| IMMUNOTHERAPEUTIC AGENT COMBINED WITH CD37, AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT | 2009 |
|
RU2531754C2 |
